SUTRO BIOPHARMA, INC. Increase (Decrease) in Accounts Receivable
SUTRO BIOPHARMA, INC. (STRO) reported Increase (Decrease) in Accounts Receivable of $1.82 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-12
- SUTRO BIOPHARMA, INC. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was -$6.69M.
- SUTRO BIOPHARMA, INC. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $8.51M, a 72.00% increase year-over-year.
- SUTRO BIOPHARMA, INC. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was $55.00K, a 97.20% decline year-over-year.
- SUTRO BIOPHARMA, INC. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was -$4.08M.
- SUTRO BIOPHARMA, INC. increase (decrease) in accounts receivable for fiscal 2025 was -$4.64M.
- SUTRO BIOPHARMA, INC. increase (decrease) in accounts receivable for fiscal 2024 was -$27.46M, a 194.84% decline from fiscal 2023.
- SUTRO BIOPHARMA, INC. increase (decrease) in accounts receivable for fiscal 2023 was $28.96M.
- SUTRO BIOPHARMA, INC. increase (decrease) in accounts receivable for fiscal 2022 was -$5.34M, a 177.46% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$6.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $1.82M 10-Q · filed 2026-08-12 | $1.88M derived: sum of 3 quarters · filed 2026-08-12 | -$2.20M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $8.51M 10-Q · filed 2026-05-14 | $8.56M derived: sum of 2 quarters · filed 2026-05-14 | $4.49M derived: sum of 3 quarters · filed 2026-05-14 | -$1.08M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $55.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$4.02M derived: sum of 2 quarters · filed 2026-03-23 | -$9.59M derived: sum of 3 quarters · filed 2026-08-12 | -$4.64M 10-K · filed 2026-03-23 |
| 2025-09-30 | -$4.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$9.64M derived: sum of 2 quarters · filed 2026-08-12 | -$4.69M 10-Q · filed 2025-11-06 | -$2.73M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$5.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$617.00K 10-Q · filed 2026-08-12 | $1.34M derived: sum of 3 quarters · filed 2026-08-12 | $1.05M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $4.95M 10-Q · filed 2026-05-14 | $6.91M derived: sum of 2 quarters · filed 2026-05-14 | $6.61M derived: sum of 3 quarters · filed 2026-05-14 | -$17.74M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $1.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $1.67M derived: sum of 2 quarters · filed 2026-03-23 | -$22.68M derived: sum of 3 quarters · filed 2026-03-23 | -$27.46M 10-K · filed 2026-03-23 |
| 2024-09-30 | -$295.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$24.64M derived: sum of 2 quarters · filed 2025-11-06 | -$29.42M 10-Q · filed 2025-11-06 | -$9.97M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$24.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$29.13M 10-Q · filed 2025-08-07 | -$9.68M derived: sum of 3 quarters · filed 2025-08-07 | -$3.05M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$4.78M 10-Q · filed 2025-05-08 | $14.67M derived: sum of 2 quarters · filed 2025-05-08 | $21.30M derived: sum of 3 quarters · filed 2025-05-08 | $21.43M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $19.45M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $26.08M derived: sum of 2 quarters · filed 2025-03-13 | $26.20M derived: sum of 3 quarters · filed 2025-03-13 | $28.96M 10-K · filed 2025-03-13 |
| 2023-09-30 | $6.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $6.75M derived: sum of 2 quarters · filed 2024-11-13 | $9.51M 10-Q · filed 2024-11-13 | $5.38M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | $126.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $2.88M 10-Q · filed 2024-08-13 | -$1.25M derived: sum of 3 quarters · filed 2025-03-13 | -$87.68M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | $2.75M 10-Q · filed 2024-05-13 | -$1.38M derived: sum of 2 quarters · filed 2025-03-13 | -$87.81M derived: sum of 3 quarters · filed 2025-03-13 | -$1.82M derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | -$4.13M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$90.56M derived: sum of 2 quarters · filed 2025-03-13 | -$4.57M derived: sum of 3 quarters · filed 2025-03-13 | -$5.34M 10-K · filed 2025-03-13 |
| 2022-09-30 | -$86.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$445.00K derived: sum of 2 quarters · filed 2023-11-13 | -$1.21M 10-Q · filed 2023-11-13 | -$1.09M derived: sum of 4 quarters · filed 2024-03-25 |
| 2022-06-30 | $85.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $85.22M 10-Q · filed 2023-08-10 | $85.34M derived: sum of 3 quarters · filed 2024-03-25 | $88.51M derived: sum of 4 quarters · filed 2024-03-25 |
| 2022-03-31 | -$768.00K 10-Q · filed 2023-05-15 | -$644.00K derived: sum of 2 quarters · filed 2024-03-25 | $2.53M derived: sum of 3 quarters · filed 2024-03-25 | $4.46M derived: sum of 4 quarters · filed 2024-03-25 |
| 2021-12-31 | $124.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $3.29M derived: sum of 2 quarters · filed 2024-03-25 | $5.23M derived: sum of 3 quarters · filed 2024-03-25 | $6.89M 10-K · filed 2024-03-25 |
| 2021-09-30 | $3.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $5.10M derived: sum of 2 quarters · filed 2022-11-08 | $6.77M 10-Q · filed 2022-11-08 | $4.85M derived: sum of 4 quarters · filed 2023-03-30 |
| 2021-06-30 | $1.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $3.60M 10-Q · filed 2022-08-08 | $1.68M derived: sum of 3 quarters · filed 2023-03-30 | $4.06M derived: sum of 4 quarters · filed 2023-03-30 |
| 2021-03-31 | $1.67M 10-Q · filed 2022-05-09 | -$256.00K derived: sum of 2 quarters · filed 2023-03-30 | $2.13M derived: sum of 3 quarters · filed 2023-03-30 | -$1.85M derived: sum of 4 quarters · filed 2023-03-30 |
| 2020-12-31 | -$1.92M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $457.00K derived: sum of 2 quarters · filed 2023-03-30 | -$3.52M derived: sum of 3 quarters · filed 2023-03-30 | -$739.00K 10-K · filed 2023-03-30 |
| 2020-09-30 | $2.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$1.60M derived: sum of 2 quarters · filed 2021-11-10 | $1.19M 10-Q · filed 2021-11-10 | -$48.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$3.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$1.20M 10-Q · filed 2021-08-09 | -$2.43M derived: sum of 3 quarters · filed 2022-02-28 | -$1.40M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $2.78M 10-Q · filed 2021-05-07 | $1.55M derived: sum of 2 quarters · filed 2022-02-28 | $2.58M derived: sum of 3 quarters · filed 2022-02-28 | $5.74M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | -$1.23M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$202.00K derived: sum of 2 quarters · filed 2022-02-28 | $2.96M derived: sum of 3 quarters · filed 2022-02-28 | $3.81M 10-K · filed 2022-02-28 |
| 2019-09-30 | $1.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $4.19M derived: sum of 2 quarters · filed 2020-11-05 | $5.04M 10-Q · filed 2020-11-05 | $5.09M derived: sum of 4 quarters · filed 2021-03-18 |
| 2019-06-30 | $3.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $4.01M 10-Q · filed 2020-08-06 | $4.06M derived: sum of 3 quarters · filed 2021-03-18 | $3.32M derived: sum of 4 quarters · filed 2021-03-18 |
| 2019-03-31 | $849.00K 10-Q · filed 2020-05-11 | $895.00K derived: sum of 2 quarters · filed 2021-03-18 | $154.00K derived: sum of 3 quarters · filed 2021-03-18 | -$817.00K derived: sum of 4 quarters · filed 2021-03-18 |
| 2018-12-31 | $46.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | -$695.00K derived: sum of 2 quarters · filed 2021-03-18 | -$1.67M derived: sum of 3 quarters · filed 2021-03-18 | $865.00K 10-K · filed 2021-03-18 |
| 2018-09-30 | -$741.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | -$1.71M derived: sum of 2 quarters · filed 2019-11-08 | $819.00K 10-Q · filed 2019-11-08 | -$8.41M derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-06-30 | -$971.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $1.56M 10-Q · filed 2019-08-14 | -$7.67M derived: sum of 3 quarters · filed 2020-03-16 | |
| 2018-03-31 | $2.53M 10-Q · filed 2019-05-15 | -$6.70M derived: sum of 2 quarters · filed 2020-03-16 | ||
| 2017-12-31 | -$9.23M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $1.05M 10-K · filed 2020-03-16 | ||
| 2017-09-30 | $10.28M 10-Q · filed 2018-11-14 | |||
| 2016-12-31 | $171.00K 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |